0
0
6/30/23 at 5:29pm
Organization
Healthday.com
Author
Elana Gotkine
43 words
0
Comments
FRIDAY, June 30, 2023 (HealthDay News) -- For patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and stage F2 or F3 fibrosis, treatment with pegozafermin leads to improvements in fibrosis, according to
You are the first to view
https://consumer.healthday.com/physician-s-briefing-nash-2661826022.html
Create an account
or login to join the discussion